2. Signaling Pathways
  3. Neuronal Signaling
  4. OGA

OGA

O-GlcNAc hydrolase; O-GlcNAcase

OGA (O-GlcNAcase) is an enzyme catalyses the removal of the O-GlcNAc post-translational modification. O-GlcNAcylation is the dynamic and ubiquitous post-translational glycosylation of nucleocytoplasmic proteins on serine/threonine residues; it is implicated in regulation of the cell cycle. O-GlcNAcylation is the dynamic and ubiquitous post-translational glycosylation of nucleocytoplasmic proteins on serine/threonine residues; it is implicated in regulation of the cell cycle.

OGA Related Products (17):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12588
    Thiamet G
    		Inhibitor 99.99%
    Thiamet G is a potent and selective inhibitor of O-GlcNAcase (OGA), which acts to remove O-GlcNAc from modified proteins, with Ki of 20 nM for human OGA.
    Thiamet G
  • HY-108241
    (Z)-PUGNAc
    		99.13%
    (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
    (Z)-PUGNAc
  • HY-144681
    Ceperognastat
    		Inhibitor 99.09%
    Ceperognastat (LY3372689) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. Ceperognastat can be used for tauopathies research, including Alzheimer’s disease.
    Ceperognastat
  • HY-130121
    MK-8719
    		99.30%
    MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (Ki=7.9 nM for hOGA) with excellent CNS penetration.
    MK-8719
  • HY-156586
    Egalognastat
    		Inhibitor 99.03%
    Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease).
    Egalognastat
  • HY-183557
    O-GlcNAcase-IN-6
    		Inhibitor
    O-GlcNAcase-IN-6 is an orally active, blood-brain barrier-permeable O-GlcNAcase (OGA) inhibitor with an IC50 of 5.4 nM. O-GlcNAcase-IN-6 inhibits OGA activity, thereby increasing the level of O-GlcNAc glycosylation in brain tissues. O-GlcNAcase-IN-6 can be used for the research of Alzheimer's disease.
    O-GlcNAcase-IN-6
  • HY-139431
    NAG-thiazoline
    		Inhibitor
    NAG-thiazoline is a O-GlcNAcase inhibitor with a Ki of 180 nM. NAG-thiazoline is a potent GH20 GlcNAcase (VhGlcNAcase) inhibitor with an IC50 of 11.9 μM and a Ki of 62 µM.
    NAG-thiazoline
  • HY-131979
    TP-040
    		98.59%
    TP-040 (O-GlcNAcase-IN-1), a chemical probe, is a potent and novel OGA inhibitor with an IC50 value of 46 nM.
    TP-040
  • HY-108032
    Hydroxyectoin
    		Inhibitor 98.0%
    Hydroxyectoin (Pyrostatin A) is a competitive inhibitor of GlcNAcase, with the Ki of 1.7 μM.
    Hydroxyectoin
  • HY-144682
    (2R,4R)-LY3372689
    O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease.
    (2R,4R)-LY3372689
  • HY-161953
    O-GlcNAcase-IN-2
    		Inhibitor
    O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects.
    O-GlcNAcase-IN-2
  • HY-148240
    JNJ-65355394
    		Inhibitor
    JNJ-65355394 (Compound 28), a chemical probe, is an O-GlcNAc hydrolase (OGA) inhibitor.
    JNJ-65355394
  • HY-144681A
    rel-Ceperognastat
    		Inhibitor
    rel-Ceperognastat (rel-LY3372689) (Compound Formula Ic) is a O-GlcNAcase (OGA) inhibitor that can be used to study the neurodegenerative diseases and disorders, such as Alzheimer's disease.
    rel-Ceperognastat
  • HY-108241R
    (Z)-PUGNAc (Standard)
    (Z)-PUGNAc (Standard) is the analytical standard of (Z)-PUGNAc (HY-108241). This product is intended for research and analytical applications. (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
    (Z)-PUGNAc (Standard)
  • HY-181600
    O-GlcNAcase-IN-4
    		Inhibitor
    O-GlcNAcase-IN-4 (compound T-110) is a O-GlcNAcase inhibitor with an IC50 of 11.59 nM. O-GlcNAcase-IN-4 modulates the activity of O-GlcNAcase. O-GlcNAcase-IN-4 is applicable to the research of neurodegenerative diseases and disorders, Alzheimer's disease, and tau-mediated neurodegenerative diseases or disorders.
    O-GlcNAcase-IN-4
  • HY-176852
    O-GlcNAcase-IN-3
    		Inhibitor
    O-GlcNAcase-IN-3 (Compound I) is an OGA inhibitor. O-GlcNAcase-IN-3 can be used for Alzheimer's Disease (AD) research.
    O-GlcNAcase-IN-3
  • HY-185146
    O-GlcNAcase-IN-5
    		Inhibitor
    O-GlcNAcase-IN-5 (Compound 1) is a selective O-GlcNAcase inhibitor. O-GlcNAcase-IN-5 can prevent the enzyme from removing the O-GlcNAc modification on tau protein, thus avoiding excessive phosphorylation of tau protein. O-GlcNAcase-IN-5 can be used for the research of Alzheimer's disease.
    O-GlcNAcase-IN-5